Tadalafil Tablet
Product Images NDC 68071-3601

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3601 3)

Tadalafil 10 mg oral tablets bottle label from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 30 tablets and displays the NDC 68071-3601-3. The label includes warnings to keep out of reach of children and storage instructions to store at controlled temperature 68-77°F. Additional barcode, lot, serial, and expiration date placeholders appear, along with manufacturer information for Zhejiang Huahai Pharmaceutical Co., China.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure of tadalafil, the active ingredient in the product TADALAFIL 10 mg oral tablets by NuCare Pharmaceuticals, Inc. The structure depicts the molecular arrangement of tadalafil with labeled functional groups and ring systems.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A set of four line graphs showing the differences in blood pressure (systolic and diastolic) between tadalafil and placebo over time (hours). The graphs display standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with differences plotted on the y-axes and time on the x-axes, including error bars.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Two line graphs showing the effect on standing and supine systolic blood pressure (mmHg) over 24 hours post-dose for tadalafil 20 mg with doxazosin 8 mg compared to placebo with doxazosin 8 mg. The y-axis represents blood pressure changes, and the x-axis indicates time after dosing in hours.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line chart displaying the systolic blood pressure (mmHg) changes over 12 hours after administration of 20 mg tadalafil or placebo combined with 8 mg doxazosin. Four data series are shown: 20 mg tadalafil at 8:00 and 20:00, and placebo at 8:00 and 20:00, each with 8 mg doxazosin at 8:00. The chart tracks systolic BP variations against time post-dosing.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph displaying plasma tadalafil concentration (μg/L) over time (hours) comparing single 20-mg and 5-mg tadalafil doses, and once-daily 5-mg tadalafil following 5 days of administration. The y-axis shows concentration from 0 to 500 μg/L, and the x-axis shows time from 0 to 120 hours. Three distinct lines illustrate concentration profiles with variation indicated by error bars.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph depicting change from baseline in IPSS Total Score over a 12-week treatment period. It compares tadalafil tablets 5 mg and placebo, showing trends of score reduction at 0, 4, 8, and 12 weeks, with tadalafil demonstrating greater reduction.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph showing the change from baseline in IPSS Total Score over 12 weeks for tadalafil 5 mg tablets versus placebo. The x-axis represents treatment duration in weeks, and the y-axis represents score change, with tadalafil showing a greater reduction in score compared to placebo throughout the study.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph comparing least-squares mean change from baseline over 26 weeks of therapy between Tadalafil/Finasteride and Placebo/Finasteride groups. The y-axis shows LS mean change from baseline, and the x-axis indicates weeks of therapy (0, 4, 12, 26). Tadalafil/Finasteride shows a greater decrease compared to Placebo/Finasteride throughout the study period, with statistical annotations for significance at certain points.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment between tadalafil tablets 5 mg and placebo. The x-axis shows duration of treatment in weeks, and the y-axis indicates change from baseline. The graph highlights statistically significant differences (p<0.01) at 12 weeks favoring tadalafil over placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.